Case Report
A Case of Endometrial Carcinosarcoma Containing Sertoliform Endometrioid Carcinoma Component
Table 2
Results of immunohistochemistry for each histological element.
| | Antibody | Sex cord-like element | Endometrioid element | | Glandular area | Solid area |
| | Cytokeratin (AE1/AE3) | 70% | 0%– | 100% | | EMA | 80% | 5% | 100% | | Vimentin | 30% | 100% | 50% | | Estrogen receptor | 0% | 0% | 2% | | Progesterone receptor | 1% | 0% | 0% | | α-Inhibin | 1% | 40% | 0% | | PAX8 | 0% | 0% | 95% | | CD99 | 90% | 95% | 90% | | Calretinin | 20% | 20% | 20% | | p16 | 50% (patchy) | 95% (diffuse) | 30% (patchy) | | p53 | 70% | 80% | 40% | | WT-1 | 0% | 0% | 0% | | Melan A | 0% | 0% | 0% | | CD56 | 80% | 60% | 10% | | Synaptophysin | 5% | 10% | 0% | | Chromogranin A | 5% | 1% | 0% | | CD10 | 0% | 0% | 0% | | α-Smooth muscle actin | 0% | 0% | 0% | | Myogenin | 0% | 0% | 0% | | β-Catenin | Membranous,
Cytoplasmic | Membranous,
Cytoplasmic | Membranous | | GATA3 | 5% | 0% | 0% | | MLH1 | 95% | 90% | 50% | | MSH2 | 90% | 90% | 90% | | MSH6 | 70% | 90% | 60% | | PMS2 | 80% | 10% (weak) | 30% (weak) | | MIB1 labeling | 34.4% | 54.8% | 21.9% |
|
|
